文献速递前列腺癌

RAFT试验:局灶治疗后机器人手术的结局

Outcomes of the RAFT trial: robotic surgery after focal therapy.
PubMed 文献 · BJU Int · 2021-05-13

23例完成12个月随访,尿控在3个月时短暂下降但12个月恢复至基线,性功能持续恶化,仅1例出现Clavien-Dindo I级并发症,12个月生化复发无生存率为82.6%。

要点

  • 局灶治疗后挽救性机器人前列腺切除术后尿控恢复良好,12个月83%无需尿垫。
  • 性功能在术后持续下降,12个月仅30%认为与术前相当或更好。
  • 术后并发症少,仅1例Clavien-Dindo I级,12个月BCFS为82.6%。

核心结论

  • RAFT试验提示局灶治疗后机器人手术毒性低,尿功能结局良好,但性功能整体恶化,12个月肿瘤学结局可接受。

主要发现

  • 中位EPIC-26尿控评分在术后3个月从基线100降至82.4,12个月恢复至100(vs 基线100,P=0.31)。
  • 中位下尿路症状评分在12个月较基线改善(93.8 vs 87.5,P=0.01)。
  • 12个月时19/23(83%)无需尿垫,22/23(96%)仅需0/1个尿垫。
  • 中位性功能评分在12个月持续低下(22.2 vs 58.3,P<0.001);以9分为最小重要差异,74%报告尿控更好或无差异,性功能相应仅30%。
  • 仅1例出现Clavien-Dindo I级术后并发症;12个月BCFS为82.6%(95%CI 60.1-93.1%),4/23(17%)接受挽救性放疗。

关键数值与推荐

  • 12个月尿控最小重要差异为9分时,17/23(74%)报告尿控更好或无差异。
  • 12个月性功能最小重要差异为12分时,7/23(30%)报告更好或无差异。
  • 12个月BCFS为82.6%(95%CI 60.1-93.1%)。

临床怎么用

  • 局灶治疗后复发选择挽救性机器人前列腺切除术前,应充分告知尿控可能恢复至基线但性功能恶化风险高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To report toxicity of treatment observed in men participating in the Robotic surgery After Focal Therapy (RAFT) clinical trial. PATIENTS AND METHODS: Men were eligible for this prospective single group interventional study if they had histologically confirmed recurrent/residual prostate adenocarcinoma following primary FT. The short-form Expanded Prostate Cancer Index Composite (EPIC-26) measured prior to salvage robotic prostatectomy (S-RARP) and 3-monthly post-operatively together with Clavien-Dindo complications (I-IV). Secondary outcomes included biochemical recurrence-free survival (BCFS) following surgery and need for salvage treatment after surgery. This study is registered with ClinicalTrials.gov NCT03011606. RESULTS: Twenty-four men were recruited between February 2016 and September 2018. 1 patient withdrew from the trial after consenting and before S-RARP. 23 men completed 12-month post S-RARP follow-up. Median EPIC-26 urinary continence scores initially deteriorated after 3 months (82.4 vs 100) but there was no statistically significant difference from baseline at 12 months (100 vs 100, P = 0.31). Median lower urinary tract symptom scores improved after 12 months compared to baseline (93.8 vs 87.5, P = 0.01). At 12 months, 19/23 (83%) were pad-free and 22/23 (96%) required 0/1 pads. Median sexual function subscale scores deteriorated and remained low at 12 months (22.2 vs 58.3, P < 0.001). Utilising a minimally important difference of nine points, at 12 months after surgery 17/23 (74%) reported urinary continence to be 'better' or 'not different' to pre-operative baseline. The corresponding figure for sexual function (utilising a minimally important difference of 12 points) was 7/23 (30%). There was no statistically significant difference on median bowel/hormonal subscale scores. Only a single patient had a post-operative complication (Clavien-Dindo Grade I). BCFS at 12 months after surgery was 82.6% (95% confidence interval [CI]: 60.1-93.1%) while 4/23 (17%) received salvage radiation. CONCLUSIONS: The RAFT clinical trial suggests toxicity of surgery after FT is low, with good urinary function outcomes, albeit sexual function deteriorated overall. Oncological outcomes at 12 months appear acceptable.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Cathcart P, Ribeiro L, Moore C, et al. Outcomes of the RAFT trial: robotic surgery after focal therapy. BJU Int. 2021. PMID: 33891378. doi:10.1111/bju.15432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。